From: Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
All N = 35 | Masitinib N = 27 | Placebo N = 8 | ||
---|---|---|---|---|
Age (years) | Mean ± SD | 48 ± 8 | 49 ± 9 | 47 ± 7 |
Min - Max | 29–61 | 29–61 | 33–56 | |
Weight (kg) | Mean ± SD | 69 ± 19 | 67 ± 19 | 74 ± 20 |
Min - Max | 43–140 | 43–140 | 54–108 | |
Male | N (%) | 17 (49) | 13 (48) | 4 (50) |
Duration of disease (years) | Mean ± SD | 9.4 ± 7.4 | 9.5 ± 7.3 | 8.8 ± 8.4 |
Min - Max | 0.2-28.6 | 0.2-28.6 | 1.5-25.6 | |
MSFC score | Mean ± SD | 0.0 ± 0.7 | -0.1 ± 0.7 | 0.3 ± 0.8 |
9-HPT (seconds) | Mean ± SD | 30 ± 9 | 30 ± 9 | 31 ± 12 |
PASAT-3” (correct answers) | Mean ± SD | 31 ± 15 | 30 ± 15 | 36 ± 15 |
T25FW* | Mean ± SD | N/A | N/A | N/A |
EDSS score | Mean ± SD | 4.9 ± 1.2 | 4.9 ± 1.2 | 5.0 ± 1.1 |